Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paxalisib - Kazia Therapeutics

Next Previous
Search
Drug Profile

Paxalisib - Kazia Therapeutics

Alternative Names: G-02441729; GDC-0084; RG 7666; SIM-0395

Latest Information Update: 06 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Alliance for Clinical Trials in Oncology; Dana-Farber Cancer Institute; Genentech; Global Coalition for Adaptive Research; Huntsman Cancer Institute; John Hopkins University; Kazia Therapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); St. Jude Childrens Research Hospital; University of California; Weill Cornell Medical College
  • Class Amines; Antineoplastics; Morpholines; Oxazines; Purines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdoid tumour; Diffuse intrinsic pontine glioma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Glioma; Lymphoma
  • Phase I/II Cancer
  • Phase I Triple negative breast cancer
  • Preclinical Malignant melanoma; Rhabdoid tumour
  • No development reported Diffuse intrinsic pontine glioma; Meningeal carcinomatosis

Most Recent Events

  • 30 Jan 2025 Phase-I clinical trials in Triple negative breast cancer(Second-line or greater therapy; Late-stage disease) in Australia (unspecified route)
  • 14 Jan 2025 Kazia Therapeutics completes a Phase-II/III GBM AGILE in Glioblastoma in USA, Australia, Canada, France, Germany, Switzerland, Austria and Italy (PO) before January 2025 (NCT03970447)
  • 31 Dec 2024 Kazia Therapeutics completes a Type C meeting with the US FDA to discuss the potential pathways to registration of paxalisib in Glioblastoma multiforme

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top